Hypoglycemia — Adult Emergency Management

Key Points

• Treat symptomatic or severe hypoglycemia immediately; do not wait for laboratory confirmation in an unstable patient.
• For most alert adults who can swallow, 15 g of fast-acting glucose followed by a glucose check in 15 minutes is standard initial treatment.
• Use IV dextrose or glucagon when the patient cannot safely take oral carbohydrate.
• Level 2 hypoglycemia is glucose below 54 mg/dL; severe level 3 hypoglycemia is defined by requiring another person for recovery.
• Long-acting insulin, sulfonylureas, renal failure, and alcohol exposure create substantial recurrence risk.
• Octreotide is important for recurrent sulfonylurea-associated hypoglycemia because dextrose alone can drive further insulin secretion.
• Every severe episode should trigger review of insulin dose, meal timing, kidney function, alcohol, exercise, and access to rescue glucagon.
• Hypoglycemia can cause focal deficits and must be excluded early in suspected stroke or unexplained altered mental status.

Algorithm

1. Check bedside glucose immediately in altered mental status, seizure, focal neurologic symptoms, or suspected medication toxicity.
2. If alert and able to swallow, give 15 g rapid glucose and recheck in 15 minutes.
3. If unable to swallow or severely impaired, give IV dextrose; use glucagon when IV access is unavailable.
4. Repeat glucose measurement and treatment until glucose is stable above 70 mg/dL and neuroglycopenic symptoms resolve.
5. Identify the cause from medication timing, meals, renal and hepatic function, alcohol, infection, endocrine disease, and exertion.
6. For sulfonylurea toxicity or recurrent hyperinsulinemic episodes, use octreotide and extended monitoring.
7. Feed a sustaining meal or carbohydrate when safe and continue serial glucose checks based on the culprit drug and clinical course.
8. Before discharge, modify the precipitating regimen, prescribe or confirm glucagon access for high-risk patients, and provide a written recurrence plan.

Clinical Synopsis & Reasoning

Symptoms include tremor, sweating, palpitations, hunger, anxiety, confusion, behavior change, visual disturbance, focal neurologic deficits, seizure, and coma. Longstanding diabetes, recurrent episodes, autonomic neuropathy, or tightly controlled glucose can blunt warning symptoms. Confirm with bedside glucose whenever possible, but do not delay treatment in an unconscious or seizing patient with a plausible hypoglycemic syndrome. Review insulin type and timing, sulfonylureas or meglitinides, missed meals, alcohol, exercise, renal or hepatic dysfunction, sepsis, adrenal insufficiency, weight loss, and medication changes. A single corrected glucose does not establish safety because long-acting insulin, sulfonylureas, renal failure, or alcohol-related impaired gluconeogenesis can produce recurrent episodes. In patients without diabetes or without an obvious medication explanation, document Whipple triad when feasible and consider endogenous hyperinsulinism, critical illness, hormone deficiency, malnutrition, or factitious exposure. During a spontaneous unexplained episode, serum glucose, insulin, C-peptide, beta-hydroxybutyrate, and a sulfonylurea/meglitinide screen can be highly informative, but emergency glucose treatment takes priority. Hypoglycemia can mimic stroke, intoxication, seizure disorder, or delirium, so glucose belongs in the first assessment of altered mental status.

Treatment Strategy & Disposition

For an alert patient who can swallow safely, give about 15 g of rapid-acting glucose or carbohydrate and recheck glucose after 15 minutes, repeating treatment until it is above 70 mg/dL and symptoms resolve. Pure glucose is preferred, although other rapidly absorbed carbohydrate can be used. Once corrected, provide a longer-acting carbohydrate or meal when appropriate if recurrence risk remains. For severe neuroglycopenia, seizure, inability to swallow, or NPO status, give IV dextrose if access is available. D10W in titrated boluses is often effective and reduces the risk of extreme transient hyperglycemia or tissue injury compared with more concentrated dextrose, although local protocols vary. If IV access is unavailable, give glucagon by an approved route and establish definitive access. Patients with sulfonylurea-associated hypoglycemia often require octreotide in addition to dextrose because dextrose itself can stimulate further insulin release; repeated glucose checks and extended observation are essential. Treat coexisting hypothermia, electrolyte abnormalities, sepsis, adrenal crisis, or hepatic failure. Adjust the responsible diabetes regimen before discharge, and ensure access to glucagon for patients treated with insulin or otherwise at high risk. Continuous glucose monitoring alarms can reduce recurrence in appropriate patients but do not replace clinical evaluation after a severe event.

Epidemiology / Risk Factors

• Hypoglycemia is common among people treated with insulin and is also seen with insulin secretagogues.
• Risk rises with older age, kidney disease, cognitive impairment, irregular food intake, prior severe episodes, and impaired awareness.
• Hospital hypoglycemia may follow interrupted nutrition, mistimed insulin, corticosteroid dose reduction, or changing renal function.
• Alcohol can impair hepatic gluconeogenesis and produce delayed hypoglycemia, especially with fasting.
• Severe recurrent hypoglycemia is associated with falls, arrhythmia, cognitive harm, and increased mortality risk.

Investigations

Common Doses

Pharmacology

Prognosis / Complications

• Neurologic symptoms usually reverse rapidly when glucose is corrected early.
• Prolonged profound hypoglycemia can cause permanent neurologic injury or death.
• Recurrence is the major short-term hazard when a long-acting drug remains active.
• A severe episode predicts future severe hypoglycemia unless the regimen and risk factors are changed.
• Structured education, CGM when appropriate, and ready access to glucagon materially improve safety for high-risk patients.

Patient Education / Counseling

• Teach patients to carry fast-acting glucose and to treat at 70 mg/dL or below according to their diabetes plan.
• Teach family, coworkers, or caregivers how and when to administer the prescribed glucagon product.
• Review the relationship between insulin, meals, exercise, alcohol, and kidney function.
• After a severe episode, temporarily avoiding driving or other hazardous activity may be necessary according to local rules and clinician guidance.
• Seek emergency care for seizure, loss of consciousness, recurrent episodes despite treatment, suspected overdose, or inability to keep glucose above the safe range.

Notes

The emergency treatment of hypoglycemia is simple only when recurrence risk is ignored. Restoring glucose is the first step, not the endpoint. The clinician should ask why the glucose fell, how long the causative drug will remain active, whether renal or hepatic function has changed, and whether the patient can recognize and treat the next episode. A safe discharge plan includes medication adjustment, rescue glucose, glucagon access where indicated, and explicit instructions for recurrent symptoms.

References

1. American Diabetes Association Standards of Care in Diabetes 2026: Glycemic Goals and Hypoglycemia — Link
2. American Diabetes Association Standards of Care in Diabetes 2026: Diabetes Care in the Hospital — Link